A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.
about
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifsEfficient adenovirus-mediated gene transfer into primary T cells and thymocytes in a new coxsackie/adenovirus receptor transgenic modelFuture of adenoviruses in the gene therapy of arthritisThe adenovirus genome contributes to the structural stability of the virionCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsAn adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyAdenoviral vector immunity: its implications and circumvention strategies.Progress in cancer gene therapy.Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organsEffects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.Gene and cell-mediated therapies for muscular dystrophy.Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration abilityDNA as therapeutics; an update.Gene therapy in the CNS.Advancements in gene transfer-based therapy for hemophilia A.Modular retro-vectors for transgenic and therapeutic use.Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective?Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vectorA novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersImprovements in adenoviral vector technology: overcoming barriers for gene therapy.Production of first generation adenovirus vectors: a review.Gene therapy for Parkinson's disease: review and update.Gene therapy in wound repair and regeneration.Gene therapy: development of immunostimulatory treatments for cancer.Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin.Novel approaches to treat muscular dystrophies.The promise and potential hazards of adenovirus gene therapy.From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system.Restenosis and gene therapy.Gene therapy for Parkinson's disease.Current strategies and future directions for eluding adenoviral vector immunity[RNA interference library research progress and its application in cancer research].Adenovirus mediated gene transfer to skeletal muscle.Adenovirus-mediated regulable target gene expression in vivo.Optimization of the helper-dependent adenovirus system for production and potency in vivo.
P2860
Q24644853-CDE4B061-DBFC-4B2B-BD54-C2705ACB8BECQ24792408-FF300962-C6A2-499D-A5A7-2DC7C42D8EA0Q24805400-EEE8CC86-F0B4-4E4E-90E0-B79CC508A950Q26825101-3821DE83-D812-4514-A28A-BA733E2F945EQ26995655-3706B5E6-42F8-417C-9E36-CFC90100F39CQ27469506-2ADBCA46-C9EA-4F79-8A2C-9B89B481F679Q28084979-EC19D9BB-0941-4E26-9B28-FAA8481DD919Q33565630-981365B8-F87A-4CEB-BBAE-C5B35D3EA975Q33752288-A57F2EAC-8401-4527-B29F-173A6A2718AAQ33815920-7E27AF10-2735-4312-A813-3D6A8BF73F39Q33817535-E448E8A2-C2C1-421B-AE68-BA430E219FFAQ33818929-3C9CBE51-CF68-4624-A471-C0EB78776F4DQ33821284-F1D8DF91-9763-4ABE-A073-89AC7F1D6DF0Q33825579-AA24D456-9451-4570-BACC-E1E16ACDD4BCQ33831193-E24FB794-75F0-4E1F-A49D-7E2728CF5E9CQ33834104-06C8B12B-A953-465F-B544-33AC4D7AB550Q33836499-5DE84901-2FFA-4E51-BCE1-F979B14B2DE8Q33837123-214F6767-DFC0-4960-A2E4-813FA06DED5FQ33923877-42D16BCB-22EB-457C-8BF5-53EF369B43BCQ33926193-6A5F2D14-22A9-4C7E-A0FF-19001EC3F53EQ33947773-97F77F47-31E0-4854-A611-C70F2F35D5C1Q33949311-945C4F44-9026-402C-9FE7-E02D9543F765Q33952908-183E5D8B-36A1-4BC6-9A0A-3A9D1AB5BA70Q33985663-2C1A5425-903A-490D-89AB-BF003418D240Q34005922-32E25C17-AB31-474F-AD1C-98DF6E103AB5Q34085243-1E45DD1F-6797-4BD8-BBEE-6902CF72E821Q34119491-03977711-76A5-4710-A2C4-3E823453CFEEQ34156741-ADC08EA9-F736-4F4A-B0C2-8952CA6B3074Q34187915-62BA75A9-FBBD-4CA7-9522-F543CBF59700Q34190967-03261E1A-E234-4117-8B22-677880EA13A6Q34204364-B40E2ED2-C2FC-47B7-9A5E-B1445735624DQ34219407-098BFABA-18A6-423E-9CD5-2439C224AAB9Q34224260-7F9BE0F0-2AB2-4FE6-B0FA-2D05B0528F7EQ34452138-34D3AD4F-CA30-473D-90B3-88A47E611DF3Q34534274-C46B2D1F-42D0-4F60-B607-D78F5E535E49Q34585554-89FE89E7-8290-4B02-B57F-50128E522705Q34593483-C91B2907-4AF8-4A99-B163-E20ED0FE860BQ34733229-F33E3080-E139-4583-88EC-D06BC20C233FQ34807993-542E6F0A-3806-4CD1-9138-444F3686E9F4Q34996749-0A6B1895-130C-47A1-B5B2-E7CDECCA345B
P2860
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@en
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@nl
type
label
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@en
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@nl
prefLabel
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@en
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@nl
P2093
P2860
P356
P1476
A new adenoviral vector: Repla ...... rophin and beta-galactosidase.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.12.5731
P407
P577
1996-06-01T00:00:00Z